Aevi Genomic Medicine to Present Updated Results from SAGA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
143
Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

PHILADELPHIA, PA--(Marketwired - Apr 12, 2017) - Aevi Genomic Medicine, Inc. ( NASDAQ : GNMX ) (the Company) today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6 th World Congress on ADHD (Attention Deficit Hyperactivity Disorder) taking place April 20-23, 2017 in Vancouver, Canada. In addition, the Company will present findings from a non-interventional phenotype/genotype study of nearly 2,000 children diagnosed with ADHD.

The data will be presented by Garry A. Neil, M.D., Chief Scientific Officer and Liza A. Squires, M.D., Vice President, Head of Neuroscience, during two poster sessions. Details are as follows:

Title:   Double-blind placebo-controlled study of the novel therapeutic AEVI-001 in adolescents with ADHD and glutamatergic network gene mutations in children and adolescents with ADHD (SAGA Trial) Presenter: Garry A. Neil, M.D., Chief Scientific Officer, Aevi Genomic Medicine, Inc. Date:  Friday, April 21, 2017, 14:30-16:00 PDT Session:  Pharmacological treatment of children and adolescents II Abstract: P-17-001 Location: Exhibition Hall A, Vancouver Convention Centre

Title:   Glutamatergic network gene mutations in children and adolescents with ADHD (Phenotype/Genotype Study) Presenter: Liza A. Squires, M.D., Vice President, Head of Neuroscience, Aevi Genomic Medicine, Inc. Date: Friday, April 21, 2017, 14:30-16:00 PDT Session:  Aetiology II Abstract: P-02-006 Location: Exhibition Hall A, Vancouver Convention Centre

About AEVI-001

AEVI-001 is an oral non-stimulant pan selective activator/modulator of mGluRs. The molecule has excellent PK and metabolic profiles and crosses the blood brain barrier.

Aevi Genomic Medicine remains committed to the development of AEVI-001 as a potential treatment for a sub-population of Attention Deficit Hyperactivity Disorder (ADHD) patients with genetic mutations that disrupt the mGluR network. The Company will also develop AEVI-001 for the treatment of autism spectrum disorder (ASD) patients with genomically identifiable mutations in the mGluR network. In the US, the CDC estimates that 6.4 million children 4-17 years of age (11%) have ever been diagnosed with ADHD. 1 Many ADHD patients remain unsatisfied with existing therapies, particularly with respect to safety, tolerability and treatment of comorbidities. In the US in 2012, 1 in 68 children were diagnosed with ASD (2012) increasing from 1 in 150 (2000) 2 . There is a high unmet need for pharmaceutical treatments for ASD as currently approved medications are indicated for symptoms of irritability in ASD patients.

AEVI-001 is an investigational agent that has not been approved by the US FDA or any other regulatory agencies.

About the SAGA Trial

SAGA was a multicenter, dose-optimized trial in adolescents with ADHD. The trial was designed as a randomized, double-blind, placebo-controlled, parallel-group study of AEVI-001 versus placebo in adolescent patients with ADHD who have genetic disorders impacting the mGluR network. The trial enrolled 101 patients (96 evaluable) between the ages of 12-17 years old. The primary and secondary endpoints in the trial were the change from baseline in the ADHD-Rating Scale Version 5 (ADHD-RS-5) Total Score and the percentage of subjects who responded as determined by the Clinical Global Impression of Improvement (CGI-I), respectively. Patients were randomized 1:1 to receive either a six-week course of AEVI-001 or placebo, with a one-week follow-up. Patients were enrolled from sites that participated in the recent phenotype/genotype study. More information on the SAGA trial is available at www.ClinicalTrials.gov (Identifier: NCT02777931).

About Aevi Genomic Medicine, Inc.

Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the Company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.

The Company is also progressing its second program, AEVI-002 into clinical development for Severe Pediatric Onset Crohn's Disease.

More information on the Company and pipeline is located on its website www.aevigenomics.com

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

Sources 1 https://www.cdc.gov/ncbddd/adhd/data.html 2 https://www.cdc.gov/ncbddd/autism/data.html

CONTACT: Aevi Genomic Medicine, Inc. Brian Piper Email Contact Westwicke Partners Chris Brinzey +1-339-970-2843 Email Contact MEDIA INQUIRIES: FTI Consulting Irma Gomez-Dib +1-212-850-5761 +1-415-706-9155 http://irma.gomez-dib@fticonsulting.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 201

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 40

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 22

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 43

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
SK hynix Faces Fresh DRAM Collusion Risk for Investors

Updated Category News Views 102

A Memory Market Win Can Turn Sour Fast Nothing rattles a chip story quite like the word collusion showing up beside a judge’s ruling. SK hynix had been riding a powerful memory-market narrative, but investors got a blunt reminder on November 15, 2026: a proposed U.S. class action accusing SK hynix, Samsung Electronics, and Micron of restricting DRAM supply to raise...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 105

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 0

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 275

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL's Innovative Initiatives: Sustainability and Creativity Unite

Updated Category News Views 304

TCL's Commitment to Innovation and Sustainability At IFA 2024, TCL, a prominent global technology brand, showcased its unwavering dedication to innovation and sustainability. This year marks TCL's 14th consecutive appearance at the event, where the company highlighted two key initiatives: TCLGreen and TCLArt. These initiatives have attracted considerable attention as they...

Continue Reading
Western Metallica Closes Private Placement to Boost Copper Projects

Updated Category News Views 209

Western Metallica's Successful Private Placement Financing Western Metallica Resources Corp. (TSXV: WMS) has successfully completed its non-brokered private placement financing. This strategic decision allowed the company to issue a significant number of units at an appealing price point. By offering 10,833,345 units at $0.03 each, Western Metallica raised gross proceeds...

Continue Reading
Astrion's New Leadership Team Set to Drive Future Innovations

Updated Category News Views 250

Astrion Unveils Dynamic Executive Leadership Team Astrion, a leader in providing advanced engineering services and mission support to government sectors, has recently announced an exciting new executive leadership team. This strategic move aligns with their ongoing mission to deliver innovative solutions following the acquisition of Axient. With industry veteran Dave...

Continue Reading
Keyera Corp. Schedules Conference Call for Q3 2024 Results

Updated Category News Views 119

Keyera Corp. Schedules 2024 Q3 Results Conference Call Keyera Corp. has announced its timeline for the release of third-quarter results. Investors and interested parties are encouraged to take note of the important dates surrounding this announcement. When to Expect the Financial Results The financial results are set to be released before the market opens on November 14,...

Continue Reading
Netflix Partners with WWE to Revitalize Global Wrestling Fanbase

Updated Category News Views 411

Netflix and WWE Join Forces for a Live Streaming Revolution In an exciting new venture, Netflix has entered the world of live programming by teaming up with World Wrestling Entertainment (WWE) to stream its flagship show, "Raw." This collaboration marks a significant shift in how wrestling fans will experience their favorite matches, bringing the thrill of live...

Continue Reading